HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period.

AbstractINTRODUCTION:
Quality of life (QOL) in heart failure patients is severely compromised by the symptoms of the disease. Acute administration of levosimendan improves patients' symptoms for intervals of 7-10 days. The aim of this study was to assess the QOL in heart failure patients, after monthly, intermittent administration of levosimendan for a 6-month period, using 3 activity questionnaires: Specific Activity Questionnaire (SAQ), Left Ventricular Dysfunction 36 (LVD 36), and Minnesota Living with Heart Failure Questionnaire (LIhFE).
METHODS:
We prospectively studied 20 patients, age 61.0 +/- 15.7 years (mean +/- SD) with heart failure (NYHA III and IV). Levosimendan was administered intravenously for 24 hours (dose 0.1 mg/kg/min), 1 day every month for a 6-month period. Patients were asked to answer the questions of the 3 activity questionnaires SAQ, LVD36 and LIhFE before and after the end of the 6-month period.
RESULTS:
For the LIhFE (the best score is 0 and the worst 105) before levosimendan the score was 35.4 +/- 18.6 and after 6 months 22.2 +/- 13.0 (p<0.0001). SAQ (worst score is 0 and the best is 9) before levosimendan was 4.2 +/- 1.6 and after 6 months 4.7 +/- 1.3 (p<0.05). For the LVD36 (more ;right' answers, more severe condition) before levosimendan values were 52.6 +/- 26.2 and after 6 months 27.4 +/- 17.3 (p<0.0001). Before levosimendan patients had a mean left ventricular ejection fraction (LVEF) 30.3 +/- 6.9, while after 6 months the LVEF was 32.1 +/- 7.4 (p=0.01).
CONCLUSIONS:
Levosimendan treatment improved both objective echocardiographic measurements and the subjective QOL questionnaires. LIhFE and LVD36 show a significant improvement in QOL in heart failure patients after a 6-month period of monthly intermittent administration of levosimendan. The SAQ showed a very small improvement, because it describes more strenuous activity, a situation unusual for these patients, who are severely symptom limited.
AuthorsEvangelia F Papadopoulou, Sophie I Mavrogeni, Athanasios Dritsas, Dennis V Cokkinos
JournalHellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese (Hellenic J Cardiol) 2009 Jul-Aug Vol. 50 Issue 4 Pg. 269-74 ISSN: 2241-5955 [Electronic] Netherlands
PMID19622496 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan
Topics
  • Activities of Daily Living
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiotonic Agents (administration & dosage)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Heart Failure (drug therapy, physiopathology, psychology)
  • Humans
  • Hydrazones (administration & dosage)
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Prospective Studies
  • Pyridazines (administration & dosage)
  • Quality of Life
  • Simendan
  • Stroke Volume (drug effects)
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left (drug effects, physiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: